Alzheon Garners $10,000,000 Series A Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    111 Speen Street Framingham, MA 01701 USA
  • Company Description
    Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds of the financing will be used to advance Alzheon’s lead drug candidate, ALZ-801, an oral, small molecule, first-in-class inhibitor of amyloid formation and neurotoxicity, toward completion of the clinical and regulatory studies for initiation of a potential pivotal clinical study in Alzheimer’s disease in the near future.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy